Abstract: Identification of the key roles of protein kinases in signaling pathways leading to development of cancer has caused pharmacological interest to concentrate extensively on targeted therapies as a more specific and effective way for blockade of cancer progression. This review will mainly focus on inhibitors targeting these key components of cellular signaling by employing a technology-based point of view with respect to ATP-and non-ATP-competitive small molecule inhibitors and monoclonal antibodies of selected protein kinases, particularly, mammalian target of rapamycin (mTOR), BCR-ABL, MEK, p38 MAPK, EGFR PDGFR, VEGFR, HER2 and Raf. Inhibitors of the heat shock protein Hsp90 are also included in a separate section, as this protein plays an essential role for the maturation/proper activation of cancer-related protein kinases. In the following review, the molecular details of the mode of action of these inhibitors as well as the emergence of drug resistance encountered in several cases are discussed in light of the structural, molecular and clinical studies conducted so far.
INTRODUCTION
Until the early 1980s, drug discovery for cancer has conventionally focused on targeting DNA synthesis and cell division, resulting in drugs such as 1) antimetabolites, which interfere with metabolism of proliferating cells: methotrexate, 5-fluorouracil (5-FU, a drug whose metabolites disrupt RNA synthesis) [1] ; 2) alkylating/crosslinking agents, which form adducts with cellular DNA, damage DNA and result in the death of growing cells: endoxan, cisplatin (first platinum-based drug to enter clinical use), oxaliplatin (a recent advanced version of cisplatin with less toxicity) [2] and cyclophosphamide; and 3) mitosis inhibitors which target microtubules and associated proteins required in cell division: paclitaxel. Although these drugs show efficacy and are still widely in use, their lack of selectivity for tumor cells over normal cells leads to high toxicity with severe side effects. However, from the 1980s onwards, discovery of intracellular signaling and its many components has opened up a new era for targeted therapies. [3] .
Kinases and phosphatases have been acknowledged as the key components of intracellular signaling. Phosphorylation and dephosphorylation cascades within the cell require activation and/or inactivation of protein kinases and phosphatases. In this review, we cover agents targeting these key components of cellular signaling with respect to ATPand non-ATP-competitive small molecule inhibitors and monoclonal antibodies of selected protein kinases. The heat shock protein Hsp90 is also included in a separate section, as this protein plays an essential role in the maturation/proper activation of cancer-related protein kinases.
Kinases are based on two main classes: serine/threonine kinases, which phosphorylate their substrates on serine and threonine residues; and tyrosine kinases, which *Address correspondence to this author at the Biological Sciences and Bioengineering Program, Sabanci University, Orhanli-Tuzla 34956, Istanbul, Turkey; Tel: + 90 216 483 9511; Fax: + 90 216 483 9550; E-mail: huveyda@sabanciuniv.edu phosphorylate substrates on tyrosine residues. The mode of action of kinases involves two successive stages: recognition of the substrate molecule by its substrate-recognition site and transfer of a phosphate molecule from ATP to the aforementioned residues of the bound protein substrate at a nearby site known as ATP-binding site or catalytic site. Initial research to develop potential inhibitors of kinases had mainly focused on this ATP-binding site with an attempt to develop an effective ATP-competitive compound.
HISTORICAL BACKGROUND
Historically, the first ATP-competitive kinase inhibitor developed in early the 1980s was a modification of a wellknown calcium-binding protein calmodulin antagonist. When the naphthalene ring was replaced by isoquinoline, Hidaka et al. (1984) observed that the resulting compound inhibited only several protein kinases [4] . However, the lack of specificity and the fact that the compound works only at high concentrations were two serious drawbacks of this first trial [5] . Later came a surprising discovery that staurosporine, an antifungal agent produced by bacteria of the genus Streptomyces, was a nanomolar inhibitor of the serine/threonine kinase Protein Kinase C (PKC) capable of activating both Raf-MAPK and NF-κB signaling pathways [6] . However, this inhibition was still non-specific. Soon, chemically modified and more specific versions of this compound were developed. Out of these, N -benzoyl staurosporine (PKC412) has entered human clinical trials for the treatment of advanced cancers. Another, 7-hydroxy staurosporine (UCN-01), which blocks G2-to-M cell cycle progression possibly by inhibiting cell cycle check point control kinase CHK1, is also in clinical trials [7, 8] .
An inspiring discovery was introduced in 1991 by Schreiber and co-workers from the field of immunology [9] . He and his colleagues identified the mode of action of a long-ago approved immunosuppressant drug named cyclosporin. This fungus metabolite was very potent in inhibiting T cell activation (the reason of which was then unknown); hence it has been used for many years in organ transplantation cases to prevent graft rejection. In this study, Fig. (1) . Schematic representation of receptor tyrosine kinase-related Ras/Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
it was shown that cyclosporin formed a complex with its intracellular receptor protein named cyclophilin, which together inhibited a Ca +2 -calmodulin dependent protein phosphatase named calcineurin. The same study also showed that the immunophilin FK506 of a bacterium origin associates with FK-binding protein (FKBP) in a similar manner, there inhibiting calcineurin [9] . The inhibition of calcineurin prevents dephoshorylation of transcription factors of the NFAT (nuclear factor of activated T cells) family in T cells, which blocks their entry into nucleus. This prevents interleukin-2 (IL-2) transcription and hence T cell proliferation.
because this was the first time research reversed direction which proceeded from the drug to its kinase. In a short span, the mammalian homolog [mTOR (or FKBP-rapamycin associated protein-FRAP-)] and other components of the mTOR signaling pathway were identified. Rapamycin obtained FDA approval in 1999, becoming the first approved drug for clinical use observed to inhibit specifically one protein kinase. Moreover, CCI-779 (Temsirolimus) is a rapamycin analog that has shown increased pharmacological success for a wide range of cancers [13] [14] [15] . Another rapamycin analog, RAD001, has also entered human clinical trials for the treatment of cancer ( Table 1) .
mTOR is involved in Phosphatidylinositol-3 Kinase (PI3K)/Akt (Protein Kinase B)/ Phosphatase-and-TENsion homolog (PTEN) pathway. Growth-factor receptor protein tyrosine kinases (RTKs) activate PI3K, which in turn phosphorylates PIP 2 (4, 5) to convert it into the essential second messenger PIP 3 (phosphotidylinositol 3,4,5 triphosphate). PIP 3 activates 3-phosphoinositide-dependent protein kinase-1 (PDK1) and brings Akt in contact with PDK1. Akt, having been activated by PDK1, exerts its effect by promoting cell survival and proliferation strongly through several diverse ways, from downregulation of proapoptotic molecules and activation of transcription factors like NF-κB, to the promotion of protein translation and G1-to-S progression. mTOR/FRAP is the kinase substrate of Akt, activated upon phosphorylation by Akt. This explains why its specific inhibitor rapamycin has proven to have a promising anti-tumor effect [16, 17] . (The last component of this pathway is the tumor suppressor phosphatase PTEN that dephosphorylates PIP3 to PIP2, negatively regulating Akt activity) [18] (Fig. 1) .
SMALL MOLECULE INHIBITORS

ATP-Competitive Inhibitors
Given the fact that small molecule inhibitors of kinases that have been developed are mainly ATP-competitive inhibitors, it was surprising to the scientific community that these compounds were actually working at all. One challenge was to compete sufficiently with very high intracellular ATP concentration level (2-10 mM), and the other was to ensure drug specificity, since the ATP-binding site is an evolutionarily well conserved region in nearly all kinases [5] . Studies performed with the highly specific serine/threonine kinase p38 MAPK inhibitor SB203580, which belongs to a class of pyridinyl imidazoles, unraveled the mystery. Analysis of the three-dimensional structure of p38 MAPK in complex with SB203580 showed that specificity is determined largely by interaction of the compound with the residues that lie nearby, but out of the ATP-binding pocket of the kinase [19, 20] . Moreover, this 'extra' interaction with the small hydrophobic pocket just near the ATP-binding site, which ATP does not exploit, allows the inhibitor to compete effectively with ATP for active site binding [21, 22] . The more potent version, SB281832, has entered human clinical trials to prevent proinflammatory cytokine (TNFα and IL-1) biosynthesis by inhibiting p38 MAPK, for the treatment of the chronic inflammatory disease, rheumatoid arthritis.
Initial studies conducted with different MAPK family members and their site-specific mutant variants revealed that for a protein kinase to be inhibited by SB203580, the side chain of an important residue in the ATP-binding region of the kinases corresponding to Thr106 of p38 MAPK, must be no larger than that of threonine [23, 24] . Actually, sensitivity to inhibition by SB203580 is greatly enhanced when the side chain is even smaller. This finding further explains the high degree of specificity of SB203580 for p38 MAPK because almost all the other MAPK family members harbor a larger residue (i.e. methionine) at the position equivalent to Thr106 of p38 MAPK. Indeed, this position has proven to be essential for several other protein kinases such as BCR-ABL, Src, EGFR, FGFR, PDGFR and KIT as well, and has its implications for the emergence of drug resistance against these kinases, as discussed in the text below. Subsequently, BCR-ABL causes uncontrolled activation of the MAPK cascade, leading to excessive proliferation of leukocytes of the myleoid lineage (granulocytes and macrophages), and hence the disease CML. Despite the relatively low incidence of CML, ABL protein tyrosine kinase was chosen to become the target of the first drug to be rationally developed because this was also the first time that a protein kinase showed a clear difference in its activity between normal and leukaemic cells. Exploiting knowledge gained from PKC (mentioned above) as a starting point [25] , Imatinib was eventually developed after a series of timeconsuming screening and modification steps, meeting all required criteria such as specificity, toxicity, bioavailability, solubility and ADME (absorption, distribution, metabolism and excretion) features in a sufficient manner along with a strong efficacy against the constitutively active BCR-ABL in in vitro and in vivo models of Ph-positive (Ph + ) leukemias [26, 27] . Having initially been developed as an ATP-competitive inhibitor, imatinib has soon proved to play a rather enhanced role than this: X-ray crystallography showed that Imatinib inhibits the ABL kinase by extending much further into the ATP-binding site, inducing a structural transition that causes the kinase to adopt the inactive conformation [28] (Fig. 2) . In other words, although imatinib targets the relatively well-conserved nucleotidebinding domain of ABL, it can still achieve remarkable specificity by preferentially binding to a distinctive inactive (unphosphorylated) conformation of the activation loop of ABL. Interestingly, despite the facts that imatinib binds selectively to the inactive form of ABL and that the amino acid sequence of the ABL segment of BCR-ABL is identical to that of c-ABL, Imatinib is still capable of inhibiting the constitutively active fusion protein BCR-ABL with a high potency. The basis of this peculiar contradiction probably lies in the exact molecular mechanisms conferring elevated catalytic activity on BCR-ABL, which are still poorly understood [28] .
Since imatinib was the first protein kinase-selective inhibitor developed for targeted cancer therapy, there is a substantial amount of clinical data demonstrating its efficacy in CML patients. Many patients with advanced stage disease respond initially, but eventually develop resistance to imatinib and undergo disease progression, mostly due to reactivation of BCR-ABL signaling. Two common mechanisms of resistance against Imatinib are overexpression of BCR-ABL itself as a result of gene amplification and emergence of point mutations in the BCR-ABL-encoded kinase domain [25, 29] . One of the most frequently detected mutations in imatinib-resistant CML is a C-to-T single mucleotide mutation that leads to the substitution of the socalled 'gatekeeper' residue Thr315 (which corresponds to Thr106 of p38 MAPK -see above-) to an isoleucine. Being located in a hydrophobic pocket adjacent to the ATP-binding site of the wild-type kinase, Thr315 forms a critical hydrogen bond with imatinib, which renders the inhibitor able to compete effectively with intracellular ATP levels by increasing its affinity for binding. Substitution of Thr315 by a larger isoleucine residue at this gatekeeper position sterically interferes with the binding of imatinib to the mutant kinase and thereby results in the formation of drug resistance [29, 30] . Since ATP does not depend on this hydrophobic pocket for binding, it remains unaffected by T315I substitution, which is why catalytic activity, in other words tumor-promoting function, is still preserved in Imatinib-insensitive BCR-ABL variants with mutations at this site [30] .
Aside from T315I substitution, there are at least a dozen more mutational hotspots conferring varying degrees of imatinib resistance to BCR-ABL. These mutations desensitize the kinase to inhibition by imatinib either by altering amino acids that directly interact with imatinib or by destabilizing the inactive conformation of the activation loop required for Imatinib binding (see above) [31] [32] [33] . Other mechanisms of resistance to imatinib might be related to pharmacokinetic factors of drug delivery (i.e. reduced intracellular bioavailability of the free drug due to enhanced active transport of the drug out of cells [34] and/or extracellular sequestration of the drug by plasma proteins [35] ) and activation of alternative kinase pathways in compensation for the loss of BCR-ABL signaling [36, 37] .
Non-ATP-Competitive Inhibitors
Saltiel and colleagues paved the way for the discovery of a new generation of small molecule inhibitors when they were trying to develop a therapeutic drug targeting MAPK kinase-1 (MKK1/MEK1) of the well-known Ras/Raf/ MEK/ERK cascade. Even though MEK is not an oncogene product, in vitro expression of constitutively active forms of MEK is able to transform the mammalian cells [38] , providing the rationale for targeting MEK therapeutically (see "BAY 43-9006" section below for the reasoning why actually the fact that MEK is not an oncogene has turned out to be an advantage for small molecule inhibitors targeting MEK). The first compound developed, PD098059, bound strongly to a mutant (almost inactive) form of MEK that could no longer be phosphorylated by ATP, but surprisingly did not inhibit MEK that had been activated by Raf [39, 40] . Later, structural studies showed that the more potent compound PD184352 (also called CI-1040) [41] actually binds preferentially to the inactive (unphosphorylated) form of the kinase, interacting with a hydrophobic pocket adjacent to, but distinct from, the ATP-binding site. This binding, due to a series of conformational changes, causes the kinase activation loop to stretch away and escape phosphorylation by its upstream activator Raf, which consequentially prevents the ERK activation loop from coming in contact with the catalytic ATP-binding site [42] . Thus, even though ATP binds to its site, binding of the inhibitor to a nearby site locks MEK in a closed and catalytically inactive conformation, which results in the blockade of the catalytic activity and of the phosphorylation of the ERK substrate. In other words, the inhibitor prevents the activation of MEK rather than directly inhibiting its kinase activity-a strategy employed by ATP-competitive inhibitors as discussed above (Fig. 2) . Even though phase I clinical trials were very successful and proved to be highly specific to MEK, unfortunately PD184352 failed to pass phase II clinical trials due to poor metabolic stability and bioavailability, terminating the development of this agent in 2004 [43, 44] . Research is now in progress for the development of advanced and more potent versions of CI-1040-like inhibitors, recently named as "non-ATP-competitive inhibitors" in a more convenient way (e.g. PD0325901, ARRY-142886) [44] . The finding that these small molecule inhibitors are capable of inducing conformational changes binding to a site apart from ATP-binding pocket accounts for their unique noncompetitive mechanism of inhibition and explains the remarkable specificity of these drugs, as this binding site is present in a region without sequence homology to other kinases. In the case of the small molecule inhibitors that have been discussed so far, it seems that future research will focus on these non-ATP-competitive inhibitors for their remarkable superiority over ATP-competitive inhibitors ( Table 1) .
Interestingly, a recent report demonstrates that a mutation (V600E) of B-Raf, which is the only Raf isoform capable of undergoing oncogenic mutations, is associated with enhanced and selective sensitivity to MEK inhibition by CI-1040 and PD0325901, when compared to 'wild-type' cells or cells harboring a Ras mutation [45] . The fact that mutational status of B-Raf predicts sensitivity to inhibition of MEK suggests that MEK is tightly dependent on B-Raf for its activation and that B-Raf mediates its downstream signaling essentially via the activity of its direct target MEK, whereas signaling from Ras diverges into several different targets such as B-Raf and PI3K (Fig. 1) . In the highly 'promiscuous' context of signal transduction where many cross-talks and links to alternative pathways exist, it is hard to find such 'faithful couples' like B-Raf and MEK. This finding has its implications in the development of future non-ATP-competitive inhibitors of MEK for a strategy urging that possible drug candidates should be tested on tumors harboring activating B-Raf mutations (i.e. melanomas) and not on tumors with activating Ras mutations (i.e. pancreatic and lung carcinomas), and in clinical trials of such drug candidates, the mutational status of B-Raf should be used to classify patients [46] .
RTKs and Small Molecule Inhibitors
Receptor tyrosine kinases (RTKs) have been the main targets for cancer therapy for more than 20 years. Ligand (growth factors etc.) binding induces RTK dimerization, which results in multiple transphosphorylations on tyrosine residues of the intracellular domains (also known as autophoshorylation) (Fig. 3) . A group of adaptors transduces the signal from activated RTKs to effector molecules such as PI3K and Ras, which initiate the signaling cascades, PI3K/Akt/mTOR and Ras/Raf-1/MEK/ERK respectively, which lie at the heart of cellular homeostasis (see above) [47] ( Fig. 1) . Dysregulations of these cascades such as mutations leading to constitutively active or overexpressed proteins as well as abnormal levels of extracellular stimuli are considered as the most common mechanisms of tumorigenesis.
The previously mentioned non-receptor tyrosine kinase BCR-ABL is not the only tyrosine kinase that is inhibited by the small molecule inhibitor Imatinib. The receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR) and c-KIT are also selectively inhibited by this compound [25, 48] (Table 1) . Another gene rearrangement event similar to the one creating BCR-ABL gives rise to the fusion of FIP1L1 (Fip1-like 1) and PDGFRα genes, with its chimeric product possessing constitutive tyrosine kinase activity, and is the main determinant of a rare hematological disorder known as idiopathic hypereosinophilic syndrome. The fusion protein FIP1L1-PDGFRα is highly sensitive to inhibition by Imatinib, whereas a mutation (T674I) affecting the PDGFRα residue homologous to the gatekeeper Thr315 in ABL is sufficient to confer resistance to imatinib [49] . This is similar to c-KIT activating mutations which lead to gastrointestinal stromal tumors (GIST). A GIST patient resistant to imatinib was shown to harbor an imatinibdesensitizing T670I mutation at an equivalent position to the gatekeeper Thr315 of ABL [50] .
Drug resistance developed by several receptor tyrosine kinases due to the emergence of mutations in the essential gatekeeper position can be readily overcome by smallmolecule kinase inhibitors that do not employ this hydrophobic pocket for binding [30] . The staurosporine analog PKC412 can effectively inhibit the imatinibinsensitive T674I variant of fused FIP1L1-PDGFRα both in vitro and in a murine model of myeloproliferative disease [51] . A recent report demonstrates that BAY 43-9006 (Sorafenib) is also a potent inhibitor of both wild type and T674I mutant FIP1L1-PDGFRα [52] . The corresponding T681I mutation in the closely related PDGFRβ does not cause resistance to the indolinone compound SU6668. Moreover, SU6668-related inhibitors are effective against FGFR1 and Src mutants harboring a methionine in the gatekeeper position (V561M and T341M, respectively) [53] .
Iressa (ZD1839/Gefitinib) has been launched as the small molecule inhibitor of epidermal growth factor receptor (EGFR) for the treatment of advanced non-small-cell lung cancer after it was approved by the FDA in May 2003. EGFR (HER1/ErbB1) is a member of the ErbB tyrosine kinase family and is markedly overexpressed in a large variety of epithelial cancers, such as lung and breast cancers [54] . Gefitinib competes reversibly with the binding of ATP to the intracellular tyrosine kinase domain of EGFR with a 100-fold higher potency than other kinases [55] , thereby inhibiting receptor autophosphorylation and blocking downstream signaling specifically (Fig. 3) . Gefitinib not only inhibits proliferation, but also induces apoptosis in tumor cells through decreased Akt activity and (proapoptotic) Bad phosphorylation; increased Bax expression and caspase 3 activation. A screening of somatic genetic alterations conducted by sequencing the EGFR genes from patients with lung cancer tumors revealed a leucine to arginine mutation (L858R) in the kinase active site of EGFR which confers increased sensitivity to inhibition by gefitinib. Importantly, the presence of the mutation strikingly correlates with the clinical response to gefitinib treatment in the selected patients [56, 57] . This finding suggests that EGFR mutations may predict sensitivity to gefitinib and tell us in advance the likelihood of a lung cancer patient to respond effectively to treatment with gefitinib. OSI-774 (Erlotinib/Tarceva) is another reversible ATP-competitive small molecule inhibitor approved by FDA in 2005 [58] .
The single C-to-T nucleotide mutation of the corresponding gatekeeper residue Thr766 of EGFR again results in resistance to gefitinib at least in an in vitro model, as demonstrated by the lack of inhibition of the mutant (T766M) EGFR phosphorylation in the presence of the drug [53, 59] . Consistently, the crystal structure of the EGFR kinase domain in complex with the ATP-competitive inhibitor erlotinib, which belongs to the same class of inhibitors as gefitinib, reveals that the substitution of the gatekeeper Thr766 with a larger residue would sterically interfere with the aromatic moiety of the inhibitor, desensitizing the kinase to inhibition by erlotinib [58] . In analogy with the case of BCR-ABL, such a substitution would not affect ATP binding to the mutant EGFR, which means that the EGFR tyrosine kinase can still maintain its tumor-promoting catalytic activity [30] . However, it remains to be determined whether this particular mutation indeed occurs and confers drug resistance in gefitinib-treated patients.
As will be briefly discussed in the following section, vascular endothelial growth factor receptor (VEGFR) is another RTK targeted for effective cancer therapy due to its key role in the induction of angiogenesis. S U 5 4 1 6 (S e m a x a n i b ) is a small molecule inhibitor of the intracellular kinase domain of VEGFR-2/KDR, however, its clinical trials have been closed since April, 2002 [60] . A close analog SU6668 is at present in clinical trials, although it is not selective for VEGFR. SU6668 also inhibits FGFR (fibroblast growth factor receptor) and PDGFR as well as VEGFR [61] . PTK787/ZK222584 and CEP-7055 are two recent compounds targeting VEGFR with a high selectivity [62] [63] [64] (Table 1) .
RTKS AND MONOCLONAL ANTIBODIES
Raising monoclonal antibodies against the extracellular ligand-binding domains of RTKs has been another extensively used strategy in cancer therapy (Fig. 3) . Cetuximab (IMC-C225/Erbitux) is a recombinant human:mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of human EGFR, competitively blocking ligand-EGFR interaction and downstream signaling [65] . Upon antibody binding, EGFR is internalized into the endosomal compartment [66] , where it is subsequently degraded. Cetuximab, approved by the FDA in February 2004 for the treatment of metastatic colorectal cancer, displays promising anti-cancer activities, including inhibition of proliferation, inhibition of angiogenesis and metastasis and induction of apoptosis [67, 68] (Fig. 3) . HER2 (ErbB2/neu), which is another member of ErbB receptor tyrosine kinase family, is inhibited by a humanized monoclonal antibody H e r c e p t i n (Trastuzumab) [69] . HER2 is overexpressed to 10-100 fold in 25-30% of breast cancer patients [70] . Herceptin, approved by FDA in 1998 for the treatment of metastatic breast cancer, is directed against the extracellular domain of HER2 and appears to block receptor dimerization, activate antibody-dependent cellular cytotoxicity, inhibit angiogenesis and enhance radiosensitivity of HER2-overexpressing breast cancer cells via modulation of repair of radiation-induced DNA damage [71, 72] . Another humanized recombinant monoclonal antibody, 2C4 (Pertuzumab), which blocks HER2 hetero dimerization, is also in clinical trials. As mentioned above, the Hsp90 client protein HER2 is actually one of the most sensitive proteins to 17-AAG [73, 74] (Table 1) . 17-AAG inhibits phosphorylation of Akt prior to the loss of Akt protein levels due to the immediate degradation of HER2 induced by 17-AAG. In HER2 overexpressing breast cancer cells, 17-AAG has been reported to cause cell cycle (G1) arrest that is associated with a loss of cyclin D protein levels [75] .
Resistance to herceptin is acquired almost in 1 year due to the activation of alternative pathways or development of constitutively active downstream signaling molecules. Combination therapies seem to be an effective way to cope with the problem of drug resistance. The small molecule inhibitor of EGFR, ZD1839 (Gefitinib), is being considered for enhanced sensitization of breast cancer cells to herceptin. Another consideration is to use the mTOR inhibitor CCI-779 for this aim [76, 77] . The finding that imatinib/STI-571-resistant BCR-ABL point mutants isolated from Philadelphia chromosome-positive (Ph + ) patients still remain sensitive to 17-AAG [78] and the fact that Hsp90 is essential for the proper activation and stability of a growing list of signaling molecules (see "Hsp90 and Geldanamycin") make it tempting to speculate that 17-AAG can also be effective in the sensitization of resistant cancer cells to Herceptin when given in combination.
Vascular endothelial growth factor receptor (VEGFR) is another RTK that is preferentially targeted for effective cancer therapy. VEGFR is extensively expressed in Fig. (3) . A schematic representation of receptor tyrosine kinase activation with emphasis on different classes of inhibitors acting at different stages to block the process and thereby downstream signaling pathways. (see also Fig. 2 ) (modified from [54, 65] ). endothelial tumor cells, inducing the process of angiogenesis-the development of new blood vessels into solid tumors for supply of oxygen and nutrients and removal of waste products. A great advantage of targeting angiogenesis is that endothelial cells are genetically stable and they do not develop drug resistance in response to antiangiogenic therapy [79] . Aside from the above-mentioned small molecule inhibitors of the intracellular kinase domain of VEGFR, the monoclonal antibody strategy is also effectively used to target the extracellular domain of VEGFR or VEGF, or to prevent their interaction (Fig. 3) . FDA approved bevacizumab (Avastin) is a recombinant humanized monoclonal antibody targeting VEGF-A, one of the six isoforms of VEGF that is the most abundant and most relevant to cancer [77] .
HEAT-SHOCK PROTEIN 90 AND GELDANAMYCIN
Specificity may not always be the ultimate aim for cancer therapy, however, drugs targeting only a specific protein in a single oncogenic pathway can readily be circumvented by tumor cells, which are capable of activating an alternative pathway to sustain cell proliferation (Fig. 1) . Indeed, this emerges as one of the most common mechanisms of drug resistance. Therefore, more generic inhibitors could be of greater use to cope with advanced and/or resistancedeveloping malignancies. Heat shock protein 90-specific benzoquinone ansamycin drug, geldanamycin, is one such inhibitor. A growing list of oncogenic kinases (Akt, BCR-ABL, RTKs, some MAPKs etc.) depend on Hsp90 for their maturation/activation into functionally competent conformation [80] (Table 1) . Geldanamycin (GA) binds tightly to the ATP-binding pocket of Hsp90, inhibiting ATPase activity of Hsp90 [81] . Without the hydrolysis of ATP taking place, Hsp90 client proteins do not get released as fully mature polypeptides [82] and thus experience a prolonged residence on Hsp90, which at this point seems to direct these substrate proteins to proteasome-mediated degradation [83] . Therefore, geldanamycin is capable of blocking multiple oncogenic pathways simultaneously.
This also underlines a unique pharmacological superiority of geldanamycin [84] : The reversible inhibition of Hsp90 by geldanamycin promotes an irreversible effect on the main pharmacological cancer targets, Hsp90 client oncoproteins. Proteasome-mediated degradation of oncoproteins to amino acids saves an additional 12-24 hours for the synthesis of new oncoproteins, at a time when the tumor cells can be forced to undergo apoptosis in combination with other supplementary therapies. A less toxic version of geldanamycin, 17-AAG [85] , is currently in clinical trials, ready to enter phase II trials after having completed phase I trials successfully [86] . Interestingly, 17-AAG has recently been shown to have a 100-fold higher affinity for Hsp90 in tumor cells [87] . Therapeutic selectivity of 17-AAG for Hsp90 in tumor cells is attributed to the fact that in an effort to meet demands of the increasing number of oncogenic proteins (folding them to activationcompetent conformations), Hsp90 operates in an activated multichaperone complex in tumor cells, which makes it highly susceptible to inhibition by 17-AAG, whereas Hsp90 in normal cells is predominantly in inactive, uncomplexed form.
COMBINED STRATEGY BY RAF INHIBITOR, BAY 43-9006
The downstream effector of Ras is the serine/threonine protein kinase family of Raf proteins, which consists of three isoforms; A-Raf, B-Raf and C-Raf (also called Raf1) (Fig. 1) . B-Raf, which is the most potent isoform to be able to phosphorylate the downstream kinase MEK1, is at the same time the only isoform, presenting oncogenic mutations identified in human cancers. Activating mutations of B-Raf (mostly, substitution of Val599 residue at the kinase activation loop with a glutamate residue) have been reported in almost 70% of malignant melanomas [88] . After the finding in melanoma cell lines that RNAi depletion of BRaf, but not of A-Raf or C-Raf, blocks ERK signaling and cell proliferation [89] ; B-Raf has won a tremendous pharmacological interest as a cancer therapeutic target. Initially developed as a specific small molecule kinase inhibitor of C-Raf, BAY 43-9006 (Sorafenib) was soon found to inhibit wild-type and mutant (V599E) B-Raf, as well [90, 91] . In melanoma cell lines, BAY 43-9006 was shown to inhibit ERK activation, prevent DNA synthesis and induce cell death [92] . A crystallographic study conducted with the wild-type B-Raf kinase domain revealed that the inhibitor BAY 43-9006 binds to the ATP-binding site of the kinase, interacting further with the kinase activation loop, thereby locking the kinase in a catalytically inactive conformation [93] (Fig. 2) . In analogy both with the case of imatinib (Gleevec) targeting the oncogenic kinase BCR-ABL and with the case of CI-1040-like inhibitors targeting MEK (see above), this enhanced interaction for the inactive conformation suggests a relatively high specificity; although it has recently been reported that BAY 43-9006 is a potent inhibitor of the kinases VEGFR2 and PDGFR, as well [94] ( Table 1) .
The findings that oncogenic mutations resulting in constitutive activation of B-Raf occur mostly within the kinase activation loop and the inhibitor BAY 43-9006 interacts with this loop in its inactive conformation have made it possible to suggest that mutant B-Raf may well escape inhibition by BAY 43-9006. In one such study mentioned above [93] , activating mutations have been shown to destabilize the inactive conformation of the B-Raf activation loop in mimicry of its phosphorylation and promote a constitutively active conformation of the kinase, disrupting the binding site for the inhibitor BAY 43-9006. Therefore, in similarity to imatinib, which developed acquired resistance in clinical trials associated with the emergence of point mutations in the kinase domain of BCR-ABL [29, 31, 32] [93] . The issue of the development of drug resistance against inhibitors of kinases that are capable of undergoing oncogenic mutations has recently led the pharmacological interest to focus on kinases that lack such activating mutations, existing both in active and inactive conformations in tumor cells. The downstream effector of Raf, MEK, is one such kinase, having not been identified as an oncogene product in human malignancies so far. Therefore, in addition to their remarkable specificity and efficacy as discussed before in the text, non-ATPcompetitive inhibitors of MEK appear unlikely to encounter drug resistance in clinical trials, further emphasizing the significance of this kinase as an effective therapeutic target [44] .
CONCLUSION AND FUTURE PERSPECTIVES
This review mainly summarizes a selected list of targeted therapeutic drugs either in clinical trials or already in the market for the treatment of diverse malignancies from a technology-based point of view. Given the fact that monoclonal antibodies have a restricted site of action, current pharmacological interest mainly focuses on the development of small molecule kinase inhibitors. Emerging new non-ATP-competitive inhibitors appear to have a remarkable superiority over ATP-competitive ones due to their higher specificity. In the future, more advanced methods to screen for such inhibitors that bind to the inactive forms of kinases will be essential, based on the knowledge on catalytic and regulatory properties of kinases. Searching for important downstream molecules that are not capable of undergoing activating mutations in the course of the disease (e.g. MEK) and for molecules that are only over expressed in tumor cells (e.g. survivin) or display a tumorspecific qualitative trait (e.g. BCR-ABL, Hsp90) as well as further progress in combination therapies will help to better resolve the issues of drug resistance and tumor-selective targeting. Given the emergence of drug resistance in patients as a challenge to successful anticancer therapy, it is inevitable that future drug development strategies will have to take into consideration the molecular mechanisms of drug resistance. Hopefully, accumulation of knowledge to be acquired by such studies will finally lead us to the development of successful small molecule inhibitors, which are less susceptible to the development of resistance, and which, alone or in combination, show higher potency against disease-related signaling molecules. 
